Clinical Trials & Drug Development

COVID-19 Prevention (Omicron-specific)

Next-generation mRNA vaccine targeting multiple Omicron subvariants with improved durability and broader protection.

Melanoma (adjuvant treatment)

Individualized neoantigen therapy in combination with Keytruda for high-risk melanoma patients post-surgery.

Propionic Acidemia

mRNA therapy encoding PCCA and PCCB enzymes for this life-threatening metabolic disorder.

Pan-coronavirus protection

Novel vaccine targeting conserved regions of coronaviruses to provide broad protection against future variants and related viruses.

Duchenne Muscular Dystrophy

AAV-based gene therapy delivering micro-dystrophin for ambulatory boys with DMD aged 4-7.

Relapsed/Refractory Multiple Myeloma

Combination of subcutaneous PD-1 inhibitor with BCMA-CD3 bispecific antibody for heavily pretreated myeloma.

COVID-19 (Enhanced T-cell response)

Novel vaccine component designed to enhance T-cell immunity for longer-lasting protection regardless of variants.

Claudin-6 positive solid tumors

First-in-class combination of CAR-T cells with mRNA vaccine boosting targeting Claudin-6 in ovarian, testicular, and lung cancers.

CLDN18.2+ Gastric Cancer

Intravenously administered mRNA encoding a secreted antibody targeting Claudin 18.2.

Pediatric B-cell ALL (Expanded Age Range)

Real-world study evaluating CAR-T therapy in broader pediatric population including infants.

Metastatic Castration-Resistant Prostate Cancer

Radioligand therapy combined with pembrolizumab for enhanced tumor killing.

C3 Glomerulopathy

Oral Factor B inhibitor for complement-mediated kidney disease.

Relapsed/Refractory Multiple Myeloma

Bispecific antibody redirecting T-cells to BCMA-expressing myeloma cells.

Generalized Myasthenia Gravis

Dual complement inhibition approach combining antibody and siRNA therapy.

Early Symptomatic Alzheimer's Disease

Anti-amyloid antibody targeting N3pG amyloid for earlier-stage Alzheimer's patients.

Obesity and Type 2 Diabetes

Once-daily oral GLP-1 receptor agonist for weight management and glycemic control.

Moderate-to-Severe Atopic Dermatitis

Real-world effectiveness study in diverse patient population.

RSV Prevention in Older Adults

Evaluating duration of protection and need for revaccination with approved RSV vaccine.

Relapsed/Refractory Multiple Myeloma

BCMA-targeted ADC in combination with standard of care for myeloma.

Malaria Prevention in Children

Evaluating optimal booster schedules for sustained malaria protection in endemic regions.

Multiple Solid Tumors (Adjuvant Setting)

Master protocol evaluating pembrolizumab combinations across 12 tumor types in adjuvant setting.

Pneumococcal Disease in Adults

Next-generation pneumococcal vaccine covering 8 unique serotypes not in current vaccines.

Pulmonary Arterial Hypertension

First-in-class activin signaling inhibitor as monotherapy for treatment-naive PAH.

HR+/HER2- Metastatic Breast Cancer

Antibody-drug conjugate targeting Trop2 with novel topoisomerase I inhibitor payload.

RSV Prevention in Infants

Real-world effectiveness study of long-acting RSV monoclonal antibody in infants.

1L Metastatic NSCLC

Novel bispecific antibody combining PD-1 and CTLA-4 blockade in single molecule.

COPD with Type 2 Inflammation

IL-4/IL-13 blockade for COPD patients with eosinophilic phenotype.

Moderate-to-Severe Asthma

Monoclonal antibody targeting IL-33, a key upstream cytokine in allergic inflammation.

Immune Thrombocytopenia (ITP)

Oral reversible BTK inhibitor for chronic ITP patients.